Search

Actiphage is a commercially-available, phage-based diagnostic developed by PBD Biotech for detection of live mycobacteria. New paper describing how Actiphage works | Press release

Dr. Thomas Böttcher, head of an Emmy Noether junior research group at the University of Konstanz in Germany has received an ERC Consolidator Grant (around 2 million Euro over 5 years) to study chemical factors that control the transition of

Two groups have published papers showing how jumbo phages can create nucleus-like structures in their hosts to protect phage DNA from CRISPR-Cas systems. Read Senén Mendoza (UCSF) and colleagues' paper on how this works for a Pseudomonas ph

The VEGA Symposium will happen March 22-23, 2020 in Oakland, CA. Hosted by the Joint Genome Institute, the goals are to bring together a “Viral Ecogenomics” community to foster discussion on how to capture and characterize uncultivated viru

The Turner lab at Yale has successfully treated 13 patients with phages so far. Now, the team has been awarded support from the Blavatnik Fund, which helps Yale scientists commercialize their discoveries. The support has made it possible fo

Anushila Chatterjee (University of Colorado) and colleagues have used transposon library screening and RNA sequencing to thoroughly investigate the interaction of E. faecalis with a virulent phage. They show that phage predation can influen

The Swiss National Science Foundation (SNSF) has announced its support of a phage project through a Sinergia Grant of more than CHF 3 million. This is a joint project between Prof. Martin Loessner of ETH Zurich, Prof. Jonas Marschall of Ber

CTV News in Canada has done a feature on phage therapy, which follows a Canadian cystic fibrosis patient as she travels to Yale University for phage treatment.

Bas Dutilh We are thinking about making virus taxonomy more consistent with the rest of biology by introducing binomial species nomenclature. You know: genus name & species epithet. Do you have an opinion about this? Let us know: Paper | IC

Ael Hardy Has anyone successfully performed proteomics (LC-MS) on whole phage particles (not bands from SDS-PAGE gels)? Looking for alternative protocols as the one I have been trying has given me a hard time. — @ael_hardy, via Twitter

Bas Dutilh We are thinking about making virus taxonomy more consistent with the rest of biology by introducing binomial species nomenclature. You know: genus name & species epithet. Do you have an opinion about this? Let us know: Paper | IC

Anushila Chatterjee (University of Colorado) and colleagues have used transposon library screening and RNA sequencing to thoroughly investigate the interaction of E. faecalis with a virulent phage. They show that phage predation can influen

Xiaofang Wang (Nanjing Agricultural University) and colleagues have studied the efficacy of different phage combinations on Ralstonia solanacearum infection of tomato plants, and found that increasing the number of phages used at a time dec

The not-for-profit healthcare organization Hackensack Meridian Health has invested in the phage biotech company Adaptive Phage Therapeutics (APT). According to APT's CEO, Greg Merril, "The high level of interest from strategic and financial

The Swiss National Science Foundation (SNSF) has announced its support of a phage project through a Sinergia Grant of more than CHF 3 million. This is a joint project between Prof. Martin Loessner of ETH Zurich, Prof. Jonas Marschall of Ber

Applications for the Pharmabiotics 2020 Young Investigators Awards are now open! This is a co-initiative by the Pharmabiotic Research Institute (PRI) and Institut Mérieux. An award of €10,000 will be allocated to a young clinician or academ

Are you attending the International Conference on Bacteriophage Research and Antimicrobial Resistance next week (Dec 12-13) in Vellore, India?

Ael Hardy Has anyone successfully performed proteomics (LC-MS) on whole phage particles (not bands from SDS-PAGE gels)? Looking for alternative protocols as the one I have been trying has given me a hard time. — @ael_hardy, via Twitter

The not-for-profit healthcare organization Hackensack Meridian Health has invested in the phage biotech company Adaptive Phage Therapeutics (APT). According to APT's CEO, Greg Merril, "The high level of interest from strategic and financial

Xiaofang Wang (Nanjing Agricultural University) and colleagues have studied the efficacy of different phage combinations on Ralstonia solanacearum infection of tomato plants, and found that increasing the number of phages used at a time dec